‘One vaccine is not enough’: Mexico aims to fix its own coronavirus virus

MEXICO CITY (Reuters) – Mexico is working to produce its own COVID-19 vaccine and may have one ready by next spring, according to a researcher, a disease caused by the coordination of local efforts between a global race Which infects 26.75 million people worldwide.

FILE PHOTO: In this illustration taken on April 10, 2020, a woman holds a small bottle labeled “Vaccine COVID-19” with stickers and a medical syringe. REUTERS / Dado Ruvic / Illustration

Esther Orozco, co-ordinator of the scientific group representing Mexico among the pandemonium-ready innovations for the coalition, said there is research based on a virus that transmits avian Newcastle disease, the first in Mexico to produce the most vaccine Is a viable candidate.

Orozco said the vaccine, developed by private firm Laboratorio Avimex with researchers from UNAM and Mexican Social Security Institute, Mexico’s main public university, is set to begin the first phase of testing with humans.

“They are upgrading,” Orozco told Reuters in an interview. “I think it’s going to be ready by spring or early summer.”

He said the Avimex vaccine trial would begin with “dozens of humans”. A second phase will see “hundreds of patients”, before thousands of volunteers participate in the final Phase 3 study.

Avimex, typically devoted to the manufacture of vaccines and pharmaceutical products for animals, did not respond to requests for comment.

Mexico has launched a global effort to forge diplomatic and commercial alliances to ensure that nearly 200 million vaccine doses are received, predicting that it would require a disease that infected more than 623,000 people. And at least 66,851 people have died in Latin America’s second largest economy.

Mexico will participate in clinical trials of Italian and Russian vaccines, and pharmaceutical firm AstraZeneca Plc (AZN.L) Vaccine.

In addition, it wants to participate in Phase 3 trials with French drug maker Sanofi (SASY.PA), Johnson & Johnson (JNJ.NCanSino Biologics Inc. (Janssen Unit) and Chinese Companies6185.HK) And Volvax Biotechnology Company Limited (300142.SZ), All of which have agreed to guarantee access to their vaccines if successful.

Orozco said the Mexican vaccine would come “later” than leading foreign candidates. But she said that 7.5 billion people on the planet would need to be vaccinated, and that the number of vaccines could double if two doses were needed.

“The world needs more than one vaccine,” she said. “We hope Mexico is a part of this, even though we are not the first to cross the finish line.”

Reporting by Anthony Esposito and Adriana Barrera; Editing by Drazen Jorgic and Dan Grebler

Our standard:Thomson Reuters Trust Theory.

Leave a Reply

Your email address will not be published.